Airing weekdays at 7:30 A.M. on

Airing weekdays at 7:30 A.M. on

No known treatment has showed significant long-term remission that is strong enough to declare a Lupus patient as cured. That was, until now.

Today, biotech experts at the French medical research company, Neovacs, are on the brink of a true landmark medical breakthrough. At Neovacs, the focus is not on drug treatment. Instead, Neovacs believes in the therapeutic philosophy of the body’s own immunity. (In other words, enhancing the immunity of the patient to develop an adequate response to fight disease.) It is currently in the advanced clinical trial stage of a therapeutic injectable vaccine for Lupus whose clinical trial results have been nothing short of astounding: Complete remission of symptoms for years, no side effects, no secondary treatments needed, and best of all, a remarkably strong immune system.

Watch The Balancing Act and see why experts are saying a cure for Lupus is, quite iterally, imminent.

Behind the Mystery is a special segment dedicated to revolutionizing the way the health care system works for those suffering from a rare and genetic disorder.

Behind the Mystery takes a closer look at one of the two types of Polycystic Kidney disease. Autosomal Dominant Polycystic Kidney Disease, or ADPKD, is a rare, genetic condition.

Behind the Mystery takes a closer look at Blastic Plasmacytoid Dendritic Cell Neoplasm, a rare disease that is often misdiagnosed and affects at least 500 to 1,000 patients each year in the U.S.

Comments

comments